Aslan Fred 4

What Happened
Fred Aslan, Chief Executive Officer of Artiva Biotherapeutics (ARTV), sold 27,116 shares on 2026-05-19 in an open-market/automatic sale for total proceeds of about $244,253. The weighted-average sale price was $9.0077 (price range $8.7383–$9.0104). The filing reports the sale as a disposition (transaction code S).

Key Details

• Transaction date: 2026-05-19 (filed same day). Filing appears timely.
• Shares sold: 27,116 at a weighted-average price of $9.0077; total proceeds ≈ $244,253.
• Price range reported: $8.7383 to $9.0104 (issuer can provide per-share price breakdown on request).
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnote F1: Sale was an automatic "sell-to-cover" to satisfy tax withholding on vested restricted stock units (not at the CEO's discretion).
• Footnote F2: Confirms weighted-average price and price range; full per-price breakdown available on request.

Context
This was a routine sell-to-cover related to RSU tax withholding, which is a common administrative transaction and not necessarily a signal about the CEO’s view of the stock. For retail investors, purchases generally carry more informational weight than automatic sales to cover taxes.